(4-chloro-3-(4-ethoxybenzyl)phenyl)((5R,6S)-6-hydroxy-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)methanone is a key chiral intermediate in the synthesis of LX4211 (Sotagliflozin). This compound features a complex molecular architecture containing a tetrahydrofuro[2,3-d][1,3]dioxolane ring system, which is a protected form of a sugar-like moiety, connected to a substituted biphenyl ketone core. Its primary and well-defined application is in the pharmaceutical manufacturing process for Sotagliflozin, a dual sodium-glucose co-transporter 1 and 2 (SGLT1/2) inhibitor. This drug was developed for the treatment of type 1 and type 2 diabetes. The specific stereochemistry ((5R,6S)-configuration) of this intermediate is crucial for the biological activity of the final API. As a sophisticated chiral building block, it represents a critical step in the synthetic route to this therapeutic agent.